IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights
Pivotal Phase 3 trial (IOB-013/KN-D18) evaluating off-the-shelf therapeutic cancer vaccine IO102-IO103 in combination with Merck’s anti-PD-1 ...
The Pharma Letter16h
Merck's Keytruda and Citius' Lymphir combo trial shows promising results
Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...
Business Insider21h
Medicenna announces single-agent activity of MDNA11 from dose expansion cohort
as monotherapy or in combination with Merck’s (MRK) anti-PD-1 therapy, KEYTRUDA, in patients with advanced solid tumors, at the 39th Annual Meeting of the Society for Immunotherapy of Cancer, held in ...
FierceBiotech23h
Rapt sees share price halve after shelving immunology drug under FDA hold
Removing zelnecirnon means the biotech’s sole remaining clinical-stage asset is tivumecirnon, a phase 2 oncology med being ...